2025 Oncologic Toxicity Management Symposium: Novel Oncology Agents and Adverse Events — On Demand

As oncology rapidly advances, next-generation therapies continue to transform the cancer treatment landscape. Recorded live on June 20, 2025, this on-demand program offers a comprehensive, evidence-based overview of emerging treatments, their clinical impact, and the practical considerations surrounding their use in practice.

Faculty experts highlight the latest breakthroughs in cancer therapeutics and toxicity management—examining mechanisms of action, clinical applications, efficacy data, and strategies to mitigate treatment-related adverse events to ultimately enhance patient care and outcomes.

This activity is designed for oncologists, hematologists, researchers, nurse practitioners, physician assistants, pharmacists, and all healthcare professionals involved in cancer care.

Through this on-demand activity, you will develop a comprehensive understanding of the mechanisms, benefits, and risks associated with cutting-edge therapies, including:

• Radioligand Therapy – A novel approach that delivers targeted radiation to cancer cells, offering precise treatment with minimal damage to surrounding tissues. The session will focus on clinical applications, effectiveness, and strategies to manage radiation-related toxicity.

• Antibody Drug Conjugates (ADCs) – A breakthrough class of targeted cancer therapies designed to deliver highly potent chemotherapy directly to cancer cells. Experts will discuss the latest ADC developments, clinical benefits, and effective management of associated toxicities.

• CAR-T Cell Therapy – A groundbreaking immunotherapy that harnesses the body’s own immune system to fight cancer. This session will address treatment protocols and management of adverse events such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

• Bispecific Antibodies – A cutting-edge approach that redirects T-cells to attack tumor cells. Attendees will gain an understanding of the potential of Bispecific Antibodies, their clinical applications, and how to mitigate immune-related toxicities.

• Small Molecule Inhibitors (SMIs) – Targeted agents that block key pathways involved in cancer growth. This session will explore the role of SMIs in oncology, their therapeutic potential, and management of associated risks such as cardiovascular toxicity and metabolic disturbances.

• Immune Checkpoint Inhibitors (ICIs) – A revolutionary class of immunotherapies that enhance the body’s natural ability to fight cancer. Experts will discuss how ICIs are reshaping oncology, the challenges of immune-related adverse events (irAEs), and best practices for toxicity management.

For a complete list of speakers and presentations, please view the brochure from the live symposium.

1. Describe the mechanism of action, indications, and clinical efficacy of Radioligand Therapy, Antibody Drug Conjugates (ADCs), Bispecific Antibodies, CAR-T Cell Therapy, Small Molecule Inhibitors (SMIs), and Immune Checkpoint Inhibitors (ICIs).
2. Develop evidence-based strategies to identify, prevent, and manage treatment-related toxicities, such as cytokine release syndrome (CRS), neurotoxicity, immune-related adverse events (irAEs), and organ-specific toxicities.
3. Recognize the early signs of adverse reactions and implement effective interventions to reduce complications and improve patient safety.
4. Apply clinical case studies and expert insights to make informed, patient-centered decisions in oncology treatment planning.
5. Discuss how to balance treatment efficacy with toxicity management to optimize long-term patient outcomes.

Access to the course content requires registration. Once registered, all materials, including instructions for claiming credit, are located under the 'Course Content' tab. For those that purchase this on demand, access to the content and the opportunity to claim credit will be available through September 30, 2026. To enroll, please click the 'Register' tab at the top of the page.

On Demand Access Fees

• Physicians (MDs, PhDs, and DOs): $300

• Advanced Practice Providers: $250

• Nurses and Other Healthcare Professionals: $200

• Residents, Fellows, and Students: $100

• MSK Employees: Complimentary

Discounted registration is available for specific groups, including complimentary registration for health professional students and registrants who reside in low and lower-middle income countries. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Please note that after your payment has been processed, no further promotional discounts or adjustments will be made to your registration.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable. For details please review our Cancellation Policy.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Recorded/Review Date: June 20, 2025; Original Release Date: October 11, 2025; Termination Date: April 30, 2026

MSK Symposium Directors

Neil J. Shah, MBBS
Assistant Attending, Solid Tumor Genitourinary Service

David Faleck, MD
Assistant Attending;
Director, Inflammatory and Immune-Related Bowel Diseases,
Gastroenterology, Hepatology & Nutrition Service

MSK Symposium Co-Directors 

Margaret Barton-Burke, PhD, RN, FAAN
Director, Nursing Research

Robert Daly, MD, MBA
Assistant Attending, Solid Tumor Thoracic Service

Steven Maron, MD, MSc
Assistant Attending, Solid Tumor Gastrointestinal Service

Urvi A. Shah, MD
Assistant Attending, Myeloma Service

Invited Symposium Faculty 

Doris Hansen, MD
Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy
Assistant Professor, Morsani College of Medicine
University of South Florida
H. Lee Moffitt Cancer Center & Research Institute

Nisha Joseph, MD
Associate Professor, Department of Hematology and Medical Oncology 
Winship Cancer Institute, Emory University

Suchita Sundaram, MD
Assistant Professor of Medicine 
Mount Sinai Icahn School of Medicine

MSK Symposium Faculty

Jie Chi, MD
Assistant Attending, Solid Tumor Breast Service

Alissa J. Cooper, MD
Assistant Attending, Solid Tumor Thoracic Service 

Daniel C. Danila, MD
Associate Attending, Solid Tumor Genitourinary Service

James Flory, MD
Associate Attending, Endocrine Service

Mark B. Geyer, MD
Assistant Attending, Leukemia and Cellular Therapy Service 

Allison Gordon, MD
Assistant Attending, Dermatology Service 

Autumn C. Guyer, MD
Associate Attending, Allergy and Immunology Service

Gopa Iyer, MD
Bladder Cancer Section Head
Associate Attending, Solid Tumor Genitourinary Service

Geoffrey Y. Ku, MD
Associate Attending, Solid Tumor Gastrointestinal Service 

Alina Markova, MD
Vice Chair, Quality, Section Head, General Dermatology and Oncodermatology
Clinical Director, Dermatology Service
Associate Attending 

Michael J. Morris, MD
Steven A. Greenberg Chair in Prostate Cancer Research
Prostate Cancer Section Head
Member and Attending, Solid Tumor Genitourinary Service  

Michael A. Postow, MD
Chief, Associate Attending, Melanoma Service 

Isabel Preeshagul, DO, MBS
Assistant Attending, Solid Tumor Thoracic Service 

Gagan Raju, MD
Assistant Attending, Adult Bone Marrow Transplantation Service

Bianca D. Santomasso, MD, PhD
Assistant Attending, Neurology Service 

Gunjan L. Shah, MD
Assistant Attending, Bone Marrow Transplant and Cellular Therapy Service

Eleni Stavrou, MD
Assistant Attending, Breast Medicine Service 

Carlyn Rose Tan, MD
Assistant Attending, Myeloma Service

Martin H. Voss, MD
Associate Attending, Solid Tumor Genitourinary Service

Serena Wong, MD 
Associate Attending, Solid Tumor Breast Service

View relevant financial relationships here.

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.